Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.

Autor: Delehaye F; Department of Pediatric Oncology and Hematology, University Hospital of Caen, Avenue de La Côte de Nacre, 14000, Caen, France. f.delehaye@gmail.com., Rouger J; Department of Pediatric Oncology and Hematology, University Hospital of Caen, Avenue de La Côte de Nacre, 14000, Caen, France., Brossier D; Pediatric Intensive Care Unit, CHU de Caen, 14000, Caen, France.; Université Caen Normandie Medical School, 14000, Caen, France., Suttorp M; Pediatric Hemato-Oncology Medical Faculty, Technical University of Dresden, Dresden, Germany., Güneş AM; Department of Pediatric Hematology, Uludağ University Hospital, Görükle, Bursa, Turkey., Sedlacek P; Department of Pediatric Hematology-Oncology, University Hospital Motole, Charles University, Prague, Czech Republic., Versluys B; Department of Pediatric Blood and Marrow Transplantation, Prinses Maxima Center, Utrecht, The Netherlands., Li CK; Department of Pediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Kalwak K; Department of Pediatric Hematology Oncology and Transplantation, Wroclaw Medical University, Wroclaw, Poland., Lausen B; Department of Pediatrics, Rigshospitalet University Hospital, Copenhagen, Denmark., Srdjana C; Department of Pediatric Hematology, Oncology Immunology, and Medical Genetic, Split, Croatia., Dworzak M; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.; St. Anna Children's Hospital Medical University of Vienna Department of Pediatrics and Adolescent Medicine, Vienna, Austria., Hraskova A; Department of Pediatric Oncology of University Children's Hospital, Bratislava, Slovakia., De Moerloose B; Department of Pediatrics, Ghent University Hospital, Ghent, Belgium., Roula F; Department of Pediatrics, Saint George Hospital, University Medical Centre, Beirut, Lebanon., Briant A; Department of Biostatistics and Clinical Research, University Hospital of Caen, Normandy, Caen, France., Parienti JJ; Department of Biostatistics and Clinical Research, University Hospital of Caen, Normandy, Caen, France., Millot F; Inserm, University Hospital, CIC 1402, Poitiers, France.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2023 Mar; Vol. 102 (3), pp. 563-570. Date of Electronic Publication: 2022 Nov 12.
DOI: 10.1007/s00277-022-05024-1
Abstrakt: The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its prevalence and its impact on prognosis are not well known. In the International Registry of Childhood CML, we selected children and adolescents in chronic phase at diagnosis of CML and treated upfront with imatinib. We examined their hemoglobin level at diagnosis according to the WHO grades to assess the prevalence of anemia and its impact on response to tyrosine kinase inhibitors (TKIs). Data on 430 patients were included. Anemia at diagnosis was observed in 350 patients (81%), with a mean hemoglobin level of 96.4 g/l (SD 23.6). Among them, 182 patients (52%) presented with moderate anemia and 110 (31%) with severe anemia while 58 (17%) had mild anemia. Compared with mild and no anemia, moderate and severe forms were significantly associated with younger age at diagnosis, asthenia, splenomegaly, and increased leukocyte and basophil counts. Delays in achieving major and deep molecular responses were significantly increased for patients with moderate and severe anemia, and also failure of imatinib treatment was more frequent in these two sub-cohorts. However, hemoglobin level was not significantly associated with survival. Anemia at diagnosis of pediatric CML was frequent and may be considered as a prognostic factor.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: